The pathophysiology of acne vulgaris in children and adolescents, part 2: Tailoring treatment

Cutis

Volumn 74, Issue 3, 2004, Pages 189-192

  Bergfeld, Wilma F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANDROGEN RECEPTOR; ANTI ACNE AGENT; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; CORTICOSTEROID; DESOGESTREL; DOXYCYCLINE; ERYTHROMYCIN; ESTROGEN; ISOTRETINOIN; MINOCYCLINE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; RECEPTOR BLOCKING AGENT; RETINOIC ACID; RETINOID; RETINOID DERIVATIVE; SALICYLIC ACID; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAZAROTENE; TETRACYCLINE;

ACNE VULGARIS; ADOLESCENT; ANTIINFLAMMATORY ACTIVITY; BACTERIAL COLONIZATION; CHILD; COMEDO; CONGENITAL HEART DISEASE; CORYNEBACTERIUM ACNES; DARIER DISEASE; DISEASE COURSE; FACE DYSMORPHIA; FETUS DISEASE; FETUS MALFORMATION; FETUS RISK; HUMAN; HYDROCEPHALUS; INFLAMMATION; NEURAL TUBE DEFECT; PATHOPHYSIOLOGY; REVIEW; SEBUM SECRETION; SKIN IRRITATION; TERATOGENICITY;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ADOLESCENT; CHILD; FEMALE; HUMANS; PRACTICE GUIDELINES; PREGNANCY; RETINOIDS; SKIN;

EID: 4944245405     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Lobo RA. Hirsutism, alopecia, and acne. In: Becker KL, Bilezikian JP, eds. Principles and Practice of Endocrinology and Metabolism. 2nd ed. Philadelphia, Pa: JB Lippincott Williams & Wilkins; 1995:924-940.
2. Kelly AP. Acne and related disorders. In: Sams WM Jr, Lynch PJ, eds. Principles and Practice of Dermatology. 2nd ed. New York, NY: Churchill Livingstone; 1996:801-818.
3. Landow K. Dispelling myths about acne. Postgrad Med. 1997;102:103-112.
4. Leyden JJ. Therapy for acne vulgaris. N Engl J Med. 1997;336:1156-1162.
5. Brown SK, Shalita AR. Acne vulgaris. Lancet. 1998;351:1871-1876.
6. Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol. 2000;142:1084-1091.
7. Toyoda M, Morohashi M. New aspects in acne inflammation. Dermatology. 2003;206:17-23.
8. Webster GF. Acne vulgaris. BMJ. 2002;325:475-479.
9. Koreck A, Pivarcsi A, Dobozy A, et al. The role of innate immunity in the pathogenesis of acne. Dermatology. 2003;206:96-105.
10. Webster GF. Acne vulgaris: state of the science. Arch Dermatol. 1999;135:1101-1102.
11. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and therapies. Semin Cutan Med Surg. 2001;20:144-153.
12. Akimoto N, Sato T, Sakiguchi T, et al. Cell proliferation and lipid formation in hamster sebaceous gland cells. Dermatology. 2002;204:118-123.
13. Gollnick HP, Krautheim A. Topical treatment in acne: current status and future aspects. Dermatology. 2003;206:29-36.
14. Wolf JE Jr. Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv Ther. 2002;19:109-118.
15. Johnson BA, Nunley JR. Topical therapy for acne vulgaris: how do you choose the best drug for each patient? Postgrad Med. 2000;107:69-80.
16. Johnson BA, Nunley JR. Use of systemic agents in the treatment of acne vulgaris. Am Fam Physician. 2000;62:1823-1836.
17. Russell JJ. Topical therapy for acne. Am Fam Physician. 2000;61:357-366.
18. Gollnick H. Current perspectives on the treatment of acne vulgaris and implications for future directions. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):1-4.
19. Krowchuk DP, Lucky AW. Managing adolescent acne. Adolesc Med. 2001;12:355-374.
20. Oberemok SS, Shalita AR. Acne vulgaris, II: treatment. Cutis. 2002;70:111-114.
21. Millikan LE. The rationale for using a topical retinoid for inflammatory acne. Am J Clin Dermatol. 2003;4:75-80.
22. Gollnick H, Cunliffe W, Berson D, et al, for the Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
23. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol. 2003;4:197-202.
24. Shaw JC. Hormonal therapies in acne. Expert Opin Pharmacother. 2002;3:865-874.
25. National and state-specific pregnancy rates among adolescents - United States, 1995-1997. MMWR Morb Mortal Wkly Rep. 2000;49:605-611.
26. Accutane-exposed pregnancies - California, 1999. MMWR Morb Mortal Wkly Rep. 2000;49:28-31.
27. Is Accutane really dangerous? Med Lett Drugs Ther. 2002;44:82.
28. Atanackovic G, Koren G. Fetal, exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program. CMAJ. 1999;160:1719-1720.
29. Tazarotene (Tazorac) for acne. Med Lett Drugs Ther. 2002;44:52-53.